Breaking News Bar

Business News and Information

Recent Quotes
My Watchlist
Indicators
Local Stocks
The Daily Herald Market Index
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Biocryst Pharma Inc (NQ: BCRX )

11.00 USD +0.22 (+2.04%)
Streaming Delayed Price Updated: 5:45 AM EST, Mar 1, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Biocryst Pharma Inc

< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Few Biotech Stocks Keep Momentum Going With Key Developments and FDA Approvals
MarketNewsUpdates.com News Commentary 
From PR Newswire
BioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that the U.S. Food... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the completion of an underwritten public offering of 17,864,078 shares of its common stock, including 2,330,097 shares sold pursuant to the... 
From GlobeNewswire News Releases
BioCryst Meeting with FDA to Design Phase III Trial for BCX7353 and PDUFA Review for RAPIVAB
From ACCESSWIRE
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced today the pricing of an underwritten public offering of 15,533,981 shares of its common stock, offered at a price to the public of $5.15 per... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Commences Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) a biotechnology company focused on the development and commercialization of treatments for rare and infectious diseases, announced today that it is offering... 
From GlobeNewswire News Releases
Technical Snapshots for These Biotech Stocks -- Alnylam Pharma, Alexion Pharma, Albany Molecular Research, and BioCryst Pharma
From PR Newswire
BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced final results from its Phase 2 APeX-1 clinical trial in hereditary angioedema (HAE). APeX-1 was a 3-part dose ranging trial designed to... 
From GlobeNewswire News Releases
BioCryst Announces Corporate Update Conference Call and Webcast
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company will host a conference call on Tuesday, September 5, 2017, at 9:00 a.m. Eastern Time to provide an update... 
From GlobeNewswire News Releases
BioCryst to Present at Three Upcoming Investor Conferences
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the... 
From GlobeNewswire News Releases
BioCryst Reports Second Quarter 2017 Financial Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the second quarter ended June 30, 2017. 
From GlobeNewswire News Releases
BioCryst Announces Initiation of ZENITH-1, a Clinical Trial to Evaluate BCX7353 as an Acute Treatment of Hereditary Angioedema Attacks
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the dosing of the first subject into ZENITH-1, a clinical trial studying up to three dosage strengths of a liquid formulation of BCX7353... 
From GlobeNewswire News Releases
BioCryst to Announce Second Quarter 2017 Financial Results on August 7
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that its second quarter 2017 financial results will be reported on Monday, August 7, 2017. 
From GlobeNewswire News Releases
BioCryst to Present at the JMP Securities 2017 Life Sciences Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the... 
From GlobeNewswire News Releases
BioCryst Announces RAPIVAB® Pediatric sNDA Acceptance
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for a pediatric... 
From GlobeNewswire News Releases
BioCryst to Present at the Jefferies 2017 Global Healthcare Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the... 
From GlobeNewswire News Releases
Robert A. Ingram Named Chairman of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today the appointment of Robert A. Ingram as Chairman of its Board of Directors. Following the Company’s annual meeting on May 24, 2017, Robert A.... 
From GlobeNewswire News Releases
BioCryst Reports Additional Positive Results From the Second Interim Analysis of Its APeX-1 Trial
125 mg dose of BCX7353 showed a reduction of 73% in overall attack rate (p=0.002) 
From GlobeNewswire News Releases
Biotech Stocks Under Scanner -- BioCryst Pharma, Biogen, Celldex Therapeutics, and Concordia
From PR Newswire
BioCryst to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that executives from the Company are scheduled to provide a corporate summary and update regarding the Company’s clinical programs at the... 
From GlobeNewswire News Releases
BioCryst Reports First Quarter 2017 Financial Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the first quarter ended March 31, 2017. 
From GlobeNewswire News Releases
BioCryst to Announce First Quarter 2017 Financial Results May 4
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2017 financial results will be reported on Thursday, May 4th, 2017. 
From GlobeNewswire News Releases
BioCryst Expands Development of BCX7353 to Explore Treatment of Acute HAE Attacks
“ZENITH-1” Clinical Trial to Evaluate an Oral Liquid Formulation 
From GlobeNewswire News Releases
BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan
A Treatment for Relapsed/Refractory Peripheral T-Cell Lymphoma 
From GlobeNewswire News Releases
BioCryst to Present at the 16th Annual Needham Healthcare Conference
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to provide a corporate update regarding the Company’s clinical programs at the 16th Annual... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the pricing of an underwritten public offering of 5,294,118 shares of its common stock, offered at a price to the public of $8.50 per share.... 
From GlobeNewswire News Releases
BioCryst Pharmaceuticals Commences Public Offering of Common Stock
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX), a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it is... 
From GlobeNewswire News Releases
BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today financial results for the fourth quarter and full year ended December 31, 2016. In a separate press release issued earlier today, BioCryst... 
From GlobeNewswire News Releases
BioCryst Reports Positive Interim Results from its APeX-1 Trial
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced results from an interim analysis of its Phase 2 APeX-1 trial in hereditary angioedema (HAE). APeX-1 is a dose ranging trial designed to... 
From GlobeNewswire News Releases
Research Reports Coverage on Biotech Stocks -- Puma Biotechnology, Dipexium Pharma, BioCryst Pharma, and CTI BioPharma
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account